Sean Grant Biography and Net Worth

CFO of Vera Therapeutics

ean Grant, MBA brings nearly 15 years of multi-disciplinary experience in healthcare and financial services. Mr. Grant joins Vera from CareDx, where he was Vice President of Corporate Strategy and Business Development. During his tenure, he led M&A, venture investments and partnerships across diagnostics, therapeutics, and digital platforms.

Prior to joining CareDx, Mr. Grant served as Vice President in the Investment Banking Healthcare Division at Citigroup. While at Citigroup, he specialized in public and private capital raising as well as M&A, and executed a broad range of transactions for many of the world’s leading life sciences companies including Gilead, Kite Pharma, and CRISPR Therapeutics. Previous to Citigroup, he held finance, strategy and business development roles at Piper Jaffray, Grant Consulting, and ESI Group.

Mr. Grant holds an MBA from the Johns Hopkins Carey School of Business and a BA in Government and International Politics from George Mason University.

What is Sean Grant's net worth?: The estimated net worth of Sean Grant is at least $4.44 million as of February 23rd, 2026. Mr. Grant owns 114,181 shares of Vera Therapeutics stock worth more than $4,437,074 as of March 29th. This net worth estimate does not reflect any other investments that Mr. Grant may own. Learn More about Sean Grant's net worth.
How do I contact Sean Grant?: The corporate mailing address for Mr. Grant and other Vera Therapeutics executives is , , . Vera Therapeutics can also be reached via phone at 650-770-0077 and via email at [email protected]. Learn More on Sean Grant's contact information.
Has Sean Grant been buying or selling shares of Vera Therapeutics?: During the last quarter, Sean Grant has sold $207,759.02 in Vera Therapeutics stock. Most recently, Sean Grant sold 4,949 shares of the business's stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $41.98, for a transaction totalling $207,759.02. Following the completion of the sale, the chief financial officer now directly owns 114,181 shares of the company's stock, valued at $4,793,318.38. Learn More on Sean Grant's trading history.
Who are Vera Therapeutics' active insiders?: Vera Therapeutics' insider roster includes Robert Brenner (Insider), Patrick Enright (Director), Marshall Fordyce (Founder), Marshall Fordyce (CEO and Founder), Sean Grant (CFO), David Johnson (COO), Maha Katabi (Director), Beth Seidenberg (Director), Laurence Skelton (Insider), William Turner (Insider), and Joseph Young (CAO). Learn More on Vera Therapeutics' active insiders.
Are insiders buying or selling shares of Vera Therapeutics?: In the last year, Vera Therapeutics insiders bought shares 3 times. They purchased a total of 255,882 shares worth more than $5,527,583.36. In the last year, insiders at the sold shares 8 times. They sold a total of 48,490 shares worth more than $1,841,810.20. The most recent insider tranaction occured on February, 23rd when insider Robert Brenner sold 2,151 shares worth more than $90,298.98. Insiders at Vera Therapeutics own 16.3% of the company. Learn More about insider trades at Vera Therapeutics.
Information on this page was last updated on 2/23/2026.

Sean Grant Insider Trading History at Vera Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/23/2026	Sell	4,949	$41.98	$207,759.02	114,181
4/3/2024	Sell	99,828	$39.61	$3,954,187.08	66,337
6/23/2023	Buy	5,000	$16.60	$83,000.00	5,992
6/15/2022	Buy	5,000	$13.60	$68,000.00	2,816

Sean Grant Buying and Selling Activity at Vera Therapeutics

Vera Therapeutics Company Overview

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Today's Range

Now: $38.86

$38.17

$40.47

50 Day Range

MA: $42.29

$38.32

$48.72

2 Week Range

Now: $38.86

$18.53

$56.05

Volume

763,127 shs

Average Volume

1,319,810 shs

Market Capitalization

$2.77 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.17